Engineered immune cells take aim at Hard-to-Treat cancers
Disease control
Recruiting now
This early-phase study tests a new treatment called NW-101C, which uses a patient's own immune cells (T-cells) that are modified in a lab to recognize and attack cancer cells carrying a specific marker (PRAME). The study enrolls up to 24 adults with advanced solid tumors who have…
Phase: PHASE1 • Sponsor: Neowise Biotechnology • Aim: Disease control
Last updated May 12, 2026 13:41 UTC